Search

Your search keyword '"Annesley, Thomas M."' showing total 257 results
Start Over Author "Annesley, Thomas M."
257 results on '"Annesley, Thomas M."'

9. Mass Spectrometry

Author

Rockwood, Alan L., primary, Annesley, Thomas M., additional, and Sherman, Nicholas E., additional

Published
2012
Full Text
View/download PDF

10. Contributors

Author

Annesley, Thomas M., primary, Apple, Fred S., additional, Ashwood, Edward R., additional, Badminton, Michael N., additional, Bais, Renze, additional, Barton, James C., additional, Baum, Howard J., additional, Bazydlo, Lindsay A.L., additional, Bechtel, Laura, additional, Bertholf, Roger L., additional, Bossler, Aaron D., additional, Bossuyt, Patrick M.M., additional, Boyd, James C., additional, Bruns, David E., additional, Burtis, Carl A., additional, Caliendo, Angela M., additional, Chan, Daniel W., additional, Chiu, Rossa W.K., additional, Deacon, Allan C., additional, Delaney, Michael P., additional, D’Orazio, Paul, additional, Doumas, Basil T., additional, Dufour, D. Robert, additional, Eckfeldt, John H., additional, Eisenhofer, Graeme, additional, Elder, George H., additional, Elenitoba-Johnson, Kojo S.J., additional, Goetze, Jens Peter, additional, Goldberger, Bruce A., additional, Grenache, David G., additional, Gronowski, Ann M., additional, Groszbach, Amy R., additional, Haverstick, Doris M., additional, Hawker, Charles D., additional, Higgins, Russell A., additional, Higgins, Trefor, additional, Hill, Peter G., additional, Holstege, Christopher P., additional, Hood, Joshua L., additional, Horowitz, Gary L., additional, Hortin, Glen L., additional, Isbell, T. Scott, additional, Jaffe, Allan S., additional, Jialal, Ishwarlal, additional, Jungheim, Emily S., additional, Karcher, Raymond E., additional, Kaumon, Malek, additional, Kitchen, Steve, additional, Klee, George G., additional, Kleerekoper, Michael, additional, Kricka, Larry J., additional, Kusukawa, Noriko, additional, Lamb, Edmund J., additional, Lambert-Messerlian, Geralyn, additional, Landers, James P., additional, Langman, Loralie, additional, LeGrys, Vicky A., additional, Linnet, Kristian, additional, Lo, Y.M. Dennis, additional, Lo, Stanley F., additional, Longo, Nicola, additional, McMillin, Gwendolyn A., additional, Meyerhoff, Mark E., additional, Moyer, Thomas P., additional, Olson, John D., additional, Panteghini, Mauro, additional, Park, Jason Y., additional, Pasquali, Marzia, additional, Price, Christopher P., additional, Rai, Alex J., additional, Remaley, Alan T., additional, Rifai, Nader, additional, Risteli, Juha, additional, Risteli, Leila, additional, Roberts, Norman B., additional, Roberts, William L., additional, Rockwood, Alan L., additional, Rosano, Thomas G., additional, Sacks, David B., additional, Schatz, Desmond, additional, Scott, Mitchell G., additional, Shenkin, Alan, additional, Sherman, Nicholas E., additional, Snozek, Christine L.H., additional, Sokoll, Lori J., additional, St. John, Andrew, additional, van Solinge, Wouter W., additional, van Wijk, Richard, additional, Vance, Mary Lee, additional, Vnencak-Jones, Cindy L., additional, Warnick, G. Russell, additional, Weedn, Victor W., additional, Westgard, James O., additional, Whatley, Sharon D., additional, Whitley, Ronald J., additional, Williams, Thomas M., additional, Winter, William E., additional, Wittwer, Carl T., additional, and Young, Donald S., additional

Published
2012
Full Text
View/download PDF

18. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial

Author

Ellis, Charles N., Fradin, Mark S., Messana, Joseph M., Brown, Marc D., Siegel, Michael T., Hartley, A. Howland, Rocher, Leslie L., Wheeler, Suzanne, Hamilton, Ted A., Parish, Thomas G., Ellis-Madu, Mary, Duell, Elizabeth, Annesley, Thomas M., Cooper, Kevin D., and Voorhees, John J.

Subjects
Cyclosporine -- Dosage and administration, Psoriasis -- Drug therapy, Cyclosporine -- Health aspects
Abstract

Cyclosporine, an immunosuppressant drug often administered to organ transplant recipients, is also effective against some forms of psoriasis (a chronic skin disease involving plaques and scales). To learn more concerning the optimal dose of cyclosporine for treating this disorder, a 16-week controlled study of 85 patients was carried out. The patients had at least one fourth of their body surface covered by plaque-type psoriasis, or severe psoriasis that was disabling, and an unsatisfactory response to standard treatments for the disease (ultraviolet light or psoralen). Patients were randomly assigned to receive daily doses of 7.5 milligrams (15 patients), 5 milligrams (20 patients), or 3 milligrams (25 patients) of oral cyclosporine per kilogram of body weight. Twenty-five patients received an inactive drug (the control group). After the first eight weeks, patients who did not improve (including controls) were adjusted to the next higher dose (those at 7.5 mg/kg went up to 10 mg/kg). Three specific lesions on each patient were rated at regular intervals during the study for scaling, redness, plaque thickness, and overall severity. In addition, overall severity and extent of involvement of the body were rated. Kidney function (which is affected by cyclosporine in many people), blood pressure, white blood cell count, and other physiological variables were also evaluated. All patients who received cyclosporine improved more than patients who received the vehicle; for the three dose levels (from lowest to highest), the decrease in the psoriasis global scores was 39, 58, and 71 percent, respectively. The best effect was in the highest-dose group (80 percent clear or almost clear of lesions). Adjustments to higher doses were required for the largest proportion of patients in the lowest-dose group (65 percent). Four patients left the study because of side effects, and four required dose reduction. Effects on renal and neurologic function were noted. The results indicate that the best initial cyclosporine dose for treating plaque-type psoriasis is 5 milligrams per kilogram per day. Additional long-term studies are needed to evaluate the drug's safety and effectiveness. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

32. Colaboradores

Author

Annesley, Thomas M., Apple, Fred S., Ashwood, Edward R., Badminton, Michael N., Bais, Renze, Barton, James C., Bazydlo, Lindsay A.L., Bechtel, Laura K., Bertholf, Roger L., Bossuyt, Patrick M.M., Boyd, James C., Bruns, David E., Burtis, Carl A., Chan, Daniel W., Chiu, Rossa W.K., Deacon, Allan C., Delaney, Michael P., DeMarco, Mari L., D'Orazio, Paul, Doumas, Basil T., Dufour, D. Robert, Eckfeldt, John H., Eisenhofer, Graeme, Elder, George H., Goetze, Jens Peter, Grenache, David G., Gronowski, Ann M., Groszbach, Amy R., Haverstick, Doris M., Hawker, Charles D., Higgins, Trefor, Hill, Peter G., Holstege, Christopher P., Horowitz, Gary L., Hortin, Glen L., Jaffe, Allan S., Jialal, Ishwarlal, Klee, George G., Kleerekoper, Michael, Kricka, Larry J., Kusukawa, Noriko, Lamb, Edmund J., Lambert-Messerlian, Geralyn, Landers, James P., Langman, Loralie, LeGrys, Vicky A., Linnet, Kristian, Lo, Stanley F., Dennis Lo, Y.M., Longo, Nicola, McMillin, Gwendolyn A., Meyerhoff, Mark E., Moyer, Thomas P., Panteghini, Mauro, Park, Jason Y., Pasquali, Marzia, Price, Christopher P., Rai, Alex J., Remaley, Alan T., Rifai, Nader, Risteli, Juha, Risteli, Leila, Roberts, Norman B., Rockwood, Alan L., Rosano, Thomas G., Rousseau, Francois A., Sacks, David B., Schatz, Desmond, Schindler, Emily I., Scott, Mitchell G., Shenkin, Alan, Sherman, Nicholas E., Snozek, Christine L.H., Sokoll, Lori J., John, Andrew St., Warnick, G. Russell, Westgard, James O., Whatley, Sharon D., Whitley, Ronald J., Winter, William E., and Wittwer, Carl T.

Published
2016

37. Effects of chronic aminodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation

Author

Cardiac Electrophysiology Section, Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Mich., USA; Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Mich., USA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Mich., USA; Cardiac Electrophysiology Section, Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Mich., USA., DiCarlo, Jr., Lorenzo A., Morady, Fred, De Buitleir, Michael, Baerman, Jeffrey M., Schurig, Lois, Annesley, Thomas M., Cardiac Electrophysiology Section, Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Mich., USA; Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Mich., USA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Mich., USA; Cardiac Electrophysiology Section, Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Mich., USA., DiCarlo, Jr., Lorenzo A., Morady, Fred, De Buitleir, Michael, Baerman, Jeffrey M., Schurig, Lois, and Annesley, Thomas M.

Abstract

Several studies have reported upon the inducibility of ventricular tachycardia (VT) with programmed ventricular stimulation (PVS) during chronic amiodarone therapy; however, few studies have systematically described and compared the morphology, duration, and cycle length of VT induced by PVS before and after amiodarone. In this study, 26 patients with symptomatic VT or ventricular fibrillation were evaluated by PVS by means of one to three extrastimuli (ES) before treatment and after 2 months of amiodarone therapy. Before amiodarone, sustained unimorphic VT was induced in 21 patients (group A) and symptomatic, nonsustained VT was induced in five patients (group B). After 65 +/- 8 days of amiodarone (total dose 64.5 +/- 8.9 gm, mean +/- S.D.), 15 of 21 patients (71%) in group A had sustained VT, five patients (24%) had nonsustained VT, and one patient had no VT induced. Four of five patients (80%) in group B had sustained VT and one patient had no VT induced. VT was induced by the same or by fewer number of ES in 79% of cases. When the morphologies of the VT induced before and after amiodarone were compared, the morphology of VT induced after amiodarone was the same in only 8 of 24 patients (33%), unimorphic but different in 14 patients (58%), and polymorphic in the remaining two patients. No correlation was found between the serum concentrations of amiodarone, desethylamiodarone, tetraiodothyronine, triiodothyronine, or reverse triiodothyroinine, and similarities or differences in VT morphology, VT cycle length, or the relative number of ES required to induce VT after treatment with amiodarone. Although VT is ofter still inducible after 2 months of amiodarone therapy, the VT induced is different from the baseline VT in the vast majority of patients.

Published
2006

38. Interrelationships between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long-term amiodarone treatment

Author

Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA., Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA. Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA., Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA; Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA, Baerman, Jeffrey M., Annesley, Thomas M., DiCarlo, Jr., Lorenzo A., Foley, Mary Kay, Nicklas, John M., Crevey, Barry J., Morady, Fred, Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA., Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA. Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA; Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA., Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA; Department of Pathology, University of Michigan Medical Center, Ann Arbor, Mich., USA, Baerman, Jeffrey M., Annesley, Thomas M., DiCarlo, Jr., Lorenzo A., Foley, Mary Kay, Nicklas, John M., Crevey, Barry J., and Morady, Fred

Abstract

The interrelationships between serum levels of amiodarone, desethylamiodarone, and reverse T3, and changes in the corrected QT interval ([Delta]QTc) were examined in 22 patients during long-term treatment with amiodarone. At 1, 3, and 6 months of follow-up, the correlation coefficient between serum levels of amiodarone or desethylamiodarone and reverse T3 ranged from 0.01 to -0.2 (p> 0.4). At the same time intervals, the correlation coefficient between both amiodarone and desethylamiodarone levels and [Delta]QTc ranged from 0.1 to -0.1 (p> 0.6), and the correlation coefficient between reverse T3 and [Delta]QTc also ranged between 0.1 to -0.1 (p> 0.5). Substituting percent [Delta]QTc for [Delta]QTc also did not reveal a significant correlation. These data demonstrate that serum levels of reverse T3 cannot be used as a substitute for serum levels of amiodarone in monitoring patients being treated with amiodarone. The absence of a correlation between serum reverse T3 levels and [Delta]QTc suggests that the delay in repolarization which occurs during amiodarone therapy is not secondary to an amiodarone-induced abnormality in thyroid hormone metabolism.

Published
2006

43. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Statement by the Consortium of Laboratory Medicine Journal Editors

Author

Rifai, Nader, primary, Annesley, Thomas M, additional, Berg, Jens P, additional, Brugnara, Carlo, additional, Delvin, Edgard, additional, Lamb, Edmund J, additional, Ness, Paul M, additional, Plebani, Mario, additional, Wick, Mark R, additional, Wu, Alan, additional, and Delanghe, Joris, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results